Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 44

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 44
---
 should set forth (i) the name and address of the shareholder as it appears on our books and, if the shares are held by a nominee, the name and address of the beneficial owner of the shares, and (ii) the number of ordinary shares that are owned of record by the record holder and beneficially by the beneficial owner. Pursuant to our Shareholder — Director Communications Policy & Procedures, the Secretary has been instructed, in his discretion, to screen out communications from shareholders that are not related to the duties and responsibilities of the board of directors. If deemed an appropriate communication, the Secretary will forward it, depending on the subject matter, to the chairperson of a committee of the board of directors or a particular director, as appropriate. 28

TABLE OF CONTENTS

EXECUTIVE OFFICERS The following table provides information concerning our executive officers as of March 21, 2025:

| Name              | ​ | ​ | Age | ​ | ​ | Position(s)                                                                    | ​ |
| Rick E Winningham | ​ | ​ |  65 | ​ | ​ | Chief Executive Officer and Director                                           | ​ |
| Rhonda F. Farnum  | ​ | ​ |  60 | ​ | ​ | Chief Business Officer and Senior Vice President, Commercial & Medical Affairs | ​ |
| Brett A. Grimaud  | ​ | ​ |  51 | ​ | ​ | Senior Vice President, General Counsel and Secretary                           | ​ |
| Aine Miller       | ​ | ​ |  48 | ​ | ​ | Senior Vice President, Development and Head of Ireland Office                  | ​ |
| Aziz Sawaf        | ​ | ​ |  43 | ​ | ​ | Senior Vice President, Chief Financial Officer                                 | ​ |

Rick E Winningham. See biographical information set forth above under “Proposal One: Election of Directors — Information Regarding the Nominees and Other Directors.” Rhonda F. Farnum was appointed Chief Business Officer and Senior Vice President, Commercial and Medical Affairs in December 2021. Ms. Farnum joined Theravance Biopharma in July 2018 as Vice President, Sales and Marketing. She is responsible for commercial execution of Theravance Biopharma’s branded products, including sales, marketing, and managed markets. Prior to joining Theravance Biopharma, Ms. Farnum led marketing efforts for multiple products in the Amgen, Inc. oncology business unit from June 2015 to July